LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: A phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Every time I see my reflection now, it feels like a quiet victorynot over vanity, but over the long, strange war between effort and biology
Animal studies have also suggested an anti-inflammatory profile
In some women, the effects of alcohol tend to be stronger and last longer
Tirzepatide Maintenance Dose After Weight Loss The clearest maintenance band is 510 mg weekly, based on the obesity dose-response curve and real-world prescribing. A 2.5 mg track has short direct data and real-world support for stable maintainers, but no long-duration maintenance trial. Continuing tirzepatide holds weight far better than stopping
Start with GHK-Cu